Amendments to the Claims:

1. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier, a protein ~~corresponding to~~ consisting of a deglycosylated kringle 1-3 region fragment of a plasminogen protein, and, optionally, a protein ~~corresponding to~~ consisting of a naturally glycosylated kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment lacks one or more carbohydrate moieties linked to naturally glycosylated forms of the fragment, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity, and wherein the amount of the naturally glycosylated kringle 1-3 region fragment present in the composition is smaller than the amount of the deglycosylated kringle 1-3 region fragment present in the composition.

2. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a bisialylated-biantennary glycan.

3. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks an N-linked carbohydrate moiety.

4. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a carbohydrate chain at amino acid position corresponding to the N-glycosylation site of human plasminogen.

5. (Cancelled)

6. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment begins at approximately amino acid 87 of human plasminogen.

7. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

8. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

9. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has an amino acid substitution at amino acid position corresponding to the N-glycosylation site of human plasminogen.

10. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment and the glycosylated form of the fragment are at a ratio of at least 60:40.

11. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment and the glycosylated form of the fragment are at a ratio of at least 80:20.

12. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment and the glycosylated form of the fragment are at a ratio of 100:0.

Claims 13-14 (Cancelled)

15. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*.

16. (Previously amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*.

Claims 17-26 (Cancelled)

27. (Previously amended) A deglycosylated kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

28. (Cancelled)